Products for Research Use Only
RegisterLogin

Nesuparib

CAT: 0804-HY-145584-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-145584-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Nesuparib (JPI-547) is the orally active inhibitor for PARP 1/2 and Tankyrase 1/2 that inhibits tankyrases 1, tankyrases 2, and PARP 1 with IC50s of 5, 1 and 2 nM, respectively. Nesuparib exhibits antitumor activity and can be used in research of advanced solid tumor[1][2][3].
CAS Number
2055357-64-5
Product Name Alternative
JPI-547/OCN-201
UNSPSC
12352005
Target
PARP; Wnt; β-catenin
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Stem Cell/Wnt
Applications
Neuroscience-Neurodegeneration
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nesuparib.html
Purity
99.54
Solubility
DMSO : 60 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
N#CC1=CN=C(N2CCN(CC2)CC3=CC(NC(C4=C5NCCC4)=O)=C5C=C3)C=C1
Molecular Formula
C23H24N6O
Molecular Weight
400.48
References & Citations
[1]Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same. Patent WO2016200101A2.|[2]Im S A , et al.A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.[J].Journal of Clinical Oncology, 2021, 39 (15_suppl) :3113-3113.|[3]Oh K S, et al. JPI-547, a dual inhibitor of PARP/Tankyrase, shows promising antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction[J]. Cancer Research, 2023, 83 (7_Supplement) : 4496-4496.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PARP2; TNKS1/PARP5A; TNKS2/PARP5B

Alternative Products

CatalogName
BA4375-5Nesuparib

Popular Products